Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29473304 | 1.00 | MEN1 (0.43) | MEN1KMT2ANPC1DGAT1TBXAS1 | |
| SCHEMBL26670573 | 0.86 | MEN1 (0.43) | MEN1KMT2ANPC1TBXAS1SMN1; SMN2 | |
| SCHEMBL4469552 | 0.82 | TBXAS1 (0.45) | MEN1KMT2ANPC1TBXAS1SMN1; SMN2 | |
| SCHEMBL26693677 | 0.82 | KMT2A (0.41) | MEN1KMT2ANPC1TBXAS1SMN1; SMN2 | |
| SCHEMBL28698607 | 0.78 | AAK1 (0.35) | TBXAS1AAK1ALDH1A1MAPTLMNA | |
| SCHEMBL26693982 | 0.76 | MEN1 (0.42) | MEN1KMT2ANPC1TBXAS1SMN1; SMN2 | |
| SCHEMBL17018473 | 0.75 | KMT2A (0.43) | MEN1KMT2ANPC1TBXAS1AAK1 | |
| SCHEMBL26670483 | 0.75 | TSHR (0.44) | MEN1KMT2ANPC1TBXAS1SMN1; SMN2 | |
| SCHEMBL29837799 | 0.74 | KMT2A (0.40) | MEN1KMT2ANPC1TBXAS1SMN1; SMN2 | |
| SCHEMBL26693646 | 0.74 | KMT2A (0.40) | MEN1KMT2ANPC1TBXAS1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4526298-A1 | PYRAZOLE DERIVATIVES AS STING AGONISTS | F. Hoffmann-La Roche AG (CH) | 2025-03-26 | — | — | EP | disclosed |
| US-20250074913-A1 | PYRAZOLE DERIVATIVES AS STING AGONISTS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-06 | — | — | US | disclosed |
| US-11845752-B2 | Substituted imidazo[1,5-a]pyrazines for the treatment of hepatitis B | ALIGOS THERAPEUTICS, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| WO-2023222644-A1 | PYRAZOLE DERIVATIVES AS STING AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023222644-A1 | PYRAZOLE DERIVATIVES AS STING AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-11-23 | — | — | WO | disclosed |
| EP-4229062-A1 | BICYCLIC COMPOUNDS | Aligos Therapeutics, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11591341-B2 | Bicyclic and tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2023-02-28 | — | — | US | disclosed |
| US-20220119395-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2022-04-21 | — | — | US | disclosed |
| WO-2022081758-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| EP-3956331-A1 | BICYCLIC AND TRICYCLIC COMPOUNDS | Aligos Therapeutics, Inc. (US) | 2022-02-23 | — | — | EP | disclosed |
| US-20200361947-A1 | BICYCLIC AND TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2020-11-19 | — | — | US | disclosed |
| WO-2020214728-A1 | BICYCLIC AND TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2020-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11845752-B2 | Substituted imidazo[1,5-a]pyrazines for the treatment of hepatitis B | SLC10A1, HAVCR2, CYP3A5 | MEN1 2681/4885KMT2A 3209/4885NPC1 69/4885 |
| US-20220119395-A1 | BICYCLIC COMPOUNDS | SLC10A1, PKD1, CYP11B2 | MEN1 262/4885KMT2A 3870/4885NPC1 11/4885 |
| US-20200361947-A1 | BICYCLIC AND TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CYP11B2 | MEN1 376/4885KMT2A 3587/4885NPC1 15/4885 |
| US-20250074913-A1 | PYRAZOLE DERIVATIVES AS STING AGONISTS | STING1, CGAS, MAVS | MEN1 2237/4885KMT2A 4029/4885NPC1 1915/4885 |
| US-11591341-B2 | Bicyclic and tricyclic compounds | SLC10A1, PKD1, CYP11B2 | MEN1 376/4885KMT2A 3587/4885NPC1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.